nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Gadoxetate—ABCC2—esophageal cancer	0.0318	1	CrCbGaD
Gadoversetamide—Pain—Carboplatin—esophageal cancer	0.00888	0.00917	CcSEcCtD
Gadoversetamide—Metrorrhagia—Capecitabine—esophageal cancer	0.00881	0.0091	CcSEcCtD
Gadoversetamide—Tongue disorder—Capecitabine—esophageal cancer	0.00865	0.00894	CcSEcCtD
Gadoversetamide—Haemoptysis—Capecitabine—esophageal cancer	0.0085	0.00878	CcSEcCtD
Gadoversetamide—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.0085	0.00878	CcSEcCtD
Gadoversetamide—Body temperature increased—Carboplatin—esophageal cancer	0.00821	0.00848	CcSEcCtD
Gadoversetamide—Rhinorrhoea—Capecitabine—esophageal cancer	0.00777	0.00802	CcSEcCtD
Gadoversetamide—Dysphonia—Capecitabine—esophageal cancer	0.00765	0.0079	CcSEcCtD
Gadoversetamide—Extrasystoles—Capecitabine—esophageal cancer	0.00748	0.00772	CcSEcCtD
Gadoversetamide—Chest discomfort—Capecitabine—esophageal cancer	0.00711	0.00735	CcSEcCtD
Gadoversetamide—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00702	0.00725	CcSEcCtD
Gadoversetamide—Hypocalcaemia—Capecitabine—esophageal cancer	0.00687	0.0071	CcSEcCtD
Gadoversetamide—Herpes simplex—Capecitabine—esophageal cancer	0.00683	0.00705	CcSEcCtD
Gadoversetamide—Nasal congestion—Cisplatin—esophageal cancer	0.0068	0.00703	CcSEcCtD
Gadoversetamide—Burning sensation—Methotrexate—esophageal cancer	0.00674	0.00696	CcSEcCtD
Gadoversetamide—Amnesia—Cisplatin—esophageal cancer	0.0066	0.00681	CcSEcCtD
Gadoversetamide—Neck pain—Capecitabine—esophageal cancer	0.00637	0.00658	CcSEcCtD
Gadoversetamide—Injection site reaction—Capecitabine—esophageal cancer	0.00626	0.00646	CcSEcCtD
Gadoversetamide—Hyponatraemia—Cisplatin—esophageal cancer	0.00622	0.00643	CcSEcCtD
Gadoversetamide—Melaena—Capecitabine—esophageal cancer	0.00615	0.00635	CcSEcCtD
Gadoversetamide—Face oedema—Cisplatin—esophageal cancer	0.00598	0.00618	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Cisplatin—esophageal cancer	0.00581	0.006	CcSEcCtD
Gadoversetamide—Ecchymosis—Capecitabine—esophageal cancer	0.00569	0.00588	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Cisplatin—esophageal cancer	0.00554	0.00572	CcSEcCtD
Gadoversetamide—Ear pain—Capecitabine—esophageal cancer	0.00535	0.00553	CcSEcCtD
Gadoversetamide—Sleep disorder—Capecitabine—esophageal cancer	0.00528	0.00545	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Capecitabine—esophageal cancer	0.00528	0.00545	CcSEcCtD
Gadoversetamide—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00522	0.00539	CcSEcCtD
Gadoversetamide—Sweating increased—Cisplatin—esophageal cancer	0.00522	0.00539	CcSEcCtD
Gadoversetamide—Herpes simplex—Methotrexate—esophageal cancer	0.00508	0.00525	CcSEcCtD
Gadoversetamide—Oliguria—Methotrexate—esophageal cancer	0.00508	0.00525	CcSEcCtD
Gadoversetamide—Eye pain—Capecitabine—esophageal cancer	0.00506	0.00523	CcSEcCtD
Gadoversetamide—Increased appetite—Capecitabine—esophageal cancer	0.00486	0.00502	CcSEcCtD
Gadoversetamide—Amnesia—Capecitabine—esophageal cancer	0.00486	0.00502	CcSEcCtD
Gadoversetamide—Thirst—Capecitabine—esophageal cancer	0.0048	0.00496	CcSEcCtD
Gadoversetamide—Conjunctivitis—Cisplatin—esophageal cancer	0.00464	0.00479	CcSEcCtD
Gadoversetamide—Hyponatraemia—Capecitabine—esophageal cancer	0.00459	0.00474	CcSEcCtD
Gadoversetamide—Melaena—Methotrexate—esophageal cancer	0.00458	0.00473	CcSEcCtD
Gadoversetamide—Diplopia—Capecitabine—esophageal cancer	0.00457	0.00472	CcSEcCtD
Gadoversetamide—Face oedema—Capecitabine—esophageal cancer	0.00441	0.00456	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Capecitabine—esophageal cancer	0.00428	0.00442	CcSEcCtD
Gadoversetamide—Ecchymosis—Methotrexate—esophageal cancer	0.00424	0.00437	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Cisplatin—esophageal cancer	0.00423	0.00437	CcSEcCtD
Gadoversetamide—Urethral disorder—Cisplatin—esophageal cancer	0.0042	0.00434	CcSEcCtD
Gadoversetamide—Dry skin—Capecitabine—esophageal cancer	0.00419	0.00432	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Capecitabine—esophageal cancer	0.00409	0.00422	CcSEcCtD
Gadoversetamide—Muscular weakness—Capecitabine—esophageal cancer	0.00403	0.00416	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00403	0.00416	CcSEcCtD
Gadoversetamide—Eye disorder—Cisplatin—esophageal cancer	0.00401	0.00414	CcSEcCtD
Gadoversetamide—Tinnitus—Cisplatin—esophageal cancer	0.004	0.00413	CcSEcCtD
Gadoversetamide—Cardiac disorder—Cisplatin—esophageal cancer	0.00398	0.00411	CcSEcCtD
Gadoversetamide—Flushing—Cisplatin—esophageal cancer	0.00398	0.00411	CcSEcCtD
Gadoversetamide—Dysphagia—Capecitabine—esophageal cancer	0.00395	0.00408	CcSEcCtD
Gadoversetamide—Asthma—Capecitabine—esophageal cancer	0.00395	0.00408	CcSEcCtD
Gadoversetamide—Influenza—Capecitabine—esophageal cancer	0.00395	0.00408	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Methotrexate—esophageal cancer	0.00393	0.00406	CcSEcCtD
Gadoversetamide—Bronchospasm—Capecitabine—esophageal cancer	0.00388	0.00401	CcSEcCtD
Gadoversetamide—Immune system disorder—Cisplatin—esophageal cancer	0.00387	0.004	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Cisplatin—esophageal cancer	0.00386	0.00399	CcSEcCtD
Gadoversetamide—Sweating increased—Capecitabine—esophageal cancer	0.00385	0.00397	CcSEcCtD
Gadoversetamide—Arrhythmia—Cisplatin—esophageal cancer	0.00383	0.00396	CcSEcCtD
Gadoversetamide—Malnutrition—Cisplatin—esophageal cancer	0.00373	0.00385	CcSEcCtD
Gadoversetamide—Erythema—Cisplatin—esophageal cancer	0.00373	0.00385	CcSEcCtD
Gadoversetamide—Dysuria—Capecitabine—esophageal cancer	0.00369	0.00381	CcSEcCtD
Gadoversetamide—Flatulence—Cisplatin—esophageal cancer	0.00368	0.0038	CcSEcCtD
Gadoversetamide—Muscle spasms—Cisplatin—esophageal cancer	0.00359	0.00371	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00356	0.00368	CcSEcCtD
Gadoversetamide—Pneumonia—Capecitabine—esophageal cancer	0.00354	0.00366	CcSEcCtD
Gadoversetamide—Vision blurred—Cisplatin—esophageal cancer	0.00352	0.00363	CcSEcCtD
Gadoversetamide—Tremor—Cisplatin—esophageal cancer	0.0035	0.00361	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00346	0.00358	CcSEcCtD
Gadoversetamide—Conjunctivitis—Capecitabine—esophageal cancer	0.00342	0.00353	CcSEcCtD
Gadoversetamide—Urinary tract infection—Capecitabine—esophageal cancer	0.00342	0.00353	CcSEcCtD
Gadoversetamide—Malaise—Cisplatin—esophageal cancer	0.00337	0.00348	CcSEcCtD
Gadoversetamide—Haematuria—Capecitabine—esophageal cancer	0.00336	0.00347	CcSEcCtD
Gadoversetamide—Epistaxis—Capecitabine—esophageal cancer	0.00332	0.00343	CcSEcCtD
Gadoversetamide—Convulsion—Cisplatin—esophageal cancer	0.00323	0.00334	CcSEcCtD
Gadoversetamide—Myalgia—Cisplatin—esophageal cancer	0.00318	0.00328	CcSEcCtD
Gadoversetamide—Haemoglobin—Capecitabine—esophageal cancer	0.00318	0.00328	CcSEcCtD
Gadoversetamide—Rhinitis—Capecitabine—esophageal cancer	0.00317	0.00327	CcSEcCtD
Gadoversetamide—Anxiety—Cisplatin—esophageal cancer	0.00317	0.00327	CcSEcCtD
Gadoversetamide—Haemorrhage—Capecitabine—esophageal cancer	0.00316	0.00326	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00316	0.00326	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Capecitabine—esophageal cancer	0.00314	0.00325	CcSEcCtD
Gadoversetamide—Discomfort—Cisplatin—esophageal cancer	0.00314	0.00324	CcSEcCtD
Gadoversetamide—Pharyngitis—Capecitabine—esophageal cancer	0.00314	0.00324	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Capecitabine—esophageal cancer	0.00312	0.00322	CcSEcCtD
Gadoversetamide—Oedema peripheral—Capecitabine—esophageal cancer	0.00311	0.00322	CcSEcCtD
Gadoversetamide—Urethral disorder—Capecitabine—esophageal cancer	0.0031	0.0032	CcSEcCtD
Gadoversetamide—Oedema—Cisplatin—esophageal cancer	0.00305	0.00315	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Cisplatin—esophageal cancer	0.00305	0.00315	CcSEcCtD
Gadoversetamide—Erythema multiforme—Capecitabine—esophageal cancer	0.00299	0.00309	CcSEcCtD
Gadoversetamide—Nervous system disorder—Cisplatin—esophageal cancer	0.00299	0.00309	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Cisplatin—esophageal cancer	0.00298	0.00308	CcSEcCtD
Gadoversetamide—Tachycardia—Cisplatin—esophageal cancer	0.00297	0.00307	CcSEcCtD
Gadoversetamide—Skin disorder—Cisplatin—esophageal cancer	0.00296	0.00306	CcSEcCtD
Gadoversetamide—Eye disorder—Capecitabine—esophageal cancer	0.00295	0.00305	CcSEcCtD
Gadoversetamide—Tinnitus—Capecitabine—esophageal cancer	0.00295	0.00304	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00294	0.00304	CcSEcCtD
Gadoversetamide—Asthma—Methotrexate—esophageal cancer	0.00294	0.00304	CcSEcCtD
Gadoversetamide—Cardiac disorder—Capecitabine—esophageal cancer	0.00293	0.00303	CcSEcCtD
Gadoversetamide—Flushing—Capecitabine—esophageal cancer	0.00293	0.00303	CcSEcCtD
Gadoversetamide—Anorexia—Cisplatin—esophageal cancer	0.0029	0.003	CcSEcCtD
Gadoversetamide—Angiopathy—Capecitabine—esophageal cancer	0.00287	0.00296	CcSEcCtD
Gadoversetamide—Immune system disorder—Capecitabine—esophageal cancer	0.00285	0.00295	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Capecitabine—esophageal cancer	0.00285	0.00294	CcSEcCtD
Gadoversetamide—Hypotension—Cisplatin—esophageal cancer	0.00285	0.00294	CcSEcCtD
Gadoversetamide—Chills—Capecitabine—esophageal cancer	0.00284	0.00293	CcSEcCtD
Gadoversetamide—Arrhythmia—Capecitabine—esophageal cancer	0.00282	0.00292	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00278	0.00287	CcSEcCtD
Gadoversetamide—Mental disorder—Capecitabine—esophageal cancer	0.00277	0.00286	CcSEcCtD
Gadoversetamide—Malnutrition—Capecitabine—esophageal cancer	0.00275	0.00284	CcSEcCtD
Gadoversetamide—Erythema—Capecitabine—esophageal cancer	0.00275	0.00284	CcSEcCtD
Gadoversetamide—Dysuria—Methotrexate—esophageal cancer	0.00275	0.00284	CcSEcCtD
Gadoversetamide—Paraesthesia—Cisplatin—esophageal cancer	0.00274	0.00282	CcSEcCtD
Gadoversetamide—Dyspnoea—Cisplatin—esophageal cancer	0.00272	0.0028	CcSEcCtD
Gadoversetamide—Flatulence—Capecitabine—esophageal cancer	0.00271	0.0028	CcSEcCtD
Gadoversetamide—Dysgeusia—Capecitabine—esophageal cancer	0.00269	0.00278	CcSEcCtD
Gadoversetamide—Back pain—Capecitabine—esophageal cancer	0.00266	0.00275	CcSEcCtD
Gadoversetamide—Decreased appetite—Cisplatin—esophageal cancer	0.00265	0.00273	CcSEcCtD
Gadoversetamide—Muscle spasms—Capecitabine—esophageal cancer	0.00265	0.00273	CcSEcCtD
Gadoversetamide—Pneumonia—Methotrexate—esophageal cancer	0.00264	0.00272	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00263	0.00272	CcSEcCtD
Gadoversetamide—Pain—Cisplatin—esophageal cancer	0.0026	0.00269	CcSEcCtD
Gadoversetamide—Vision blurred—Capecitabine—esophageal cancer	0.00259	0.00268	CcSEcCtD
Gadoversetamide—Tremor—Capecitabine—esophageal cancer	0.00258	0.00266	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Capecitabine—esophageal cancer	0.00255	0.00264	CcSEcCtD
Gadoversetamide—Conjunctivitis—Methotrexate—esophageal cancer	0.00255	0.00263	CcSEcCtD
Gadoversetamide—Feeling abnormal—Cisplatin—esophageal cancer	0.00251	0.00259	CcSEcCtD
Gadoversetamide—Haematuria—Methotrexate—esophageal cancer	0.0025	0.00258	CcSEcCtD
Gadoversetamide—Malaise—Capecitabine—esophageal cancer	0.00248	0.00256	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—esophageal cancer	0.00247	0.00255	CcSEcCtD
Gadoversetamide—Vertigo—Capecitabine—esophageal cancer	0.00247	0.00255	CcSEcCtD
Gadoversetamide—Syncope—Capecitabine—esophageal cancer	0.00247	0.00255	CcSEcCtD
Gadoversetamide—Palpitations—Capecitabine—esophageal cancer	0.00243	0.00251	CcSEcCtD
Gadoversetamide—Loss of consciousness—Capecitabine—esophageal cancer	0.00242	0.0025	CcSEcCtD
Gadoversetamide—Body temperature increased—Cisplatin—esophageal cancer	0.00241	0.00249	CcSEcCtD
Gadoversetamide—Cough—Capecitabine—esophageal cancer	0.0024	0.00248	CcSEcCtD
Gadoversetamide—Hypertension—Capecitabine—esophageal cancer	0.00238	0.00245	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—esophageal cancer	0.00236	0.00244	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—esophageal cancer	0.00235	0.00243	CcSEcCtD
Gadoversetamide—Arthralgia—Capecitabine—esophageal cancer	0.00234	0.00242	CcSEcCtD
Gadoversetamide—Chest pain—Capecitabine—esophageal cancer	0.00234	0.00242	CcSEcCtD
Gadoversetamide—Myalgia—Capecitabine—esophageal cancer	0.00234	0.00242	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—esophageal cancer	0.00234	0.00241	CcSEcCtD
Gadoversetamide—Anxiety—Capecitabine—esophageal cancer	0.00233	0.00241	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00233	0.0024	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00232	0.0024	CcSEcCtD
Gadoversetamide—Discomfort—Capecitabine—esophageal cancer	0.00231	0.00239	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—esophageal cancer	0.00231	0.00238	CcSEcCtD
Gadoversetamide—Dry mouth—Capecitabine—esophageal cancer	0.00229	0.00237	CcSEcCtD
Gadoversetamide—Confusional state—Capecitabine—esophageal cancer	0.00226	0.00234	CcSEcCtD
Gadoversetamide—Oedema—Capecitabine—esophageal cancer	0.00225	0.00232	CcSEcCtD
Gadoversetamide—Hypersensitivity—Cisplatin—esophageal cancer	0.00224	0.00232	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—esophageal cancer	0.00222	0.0023	CcSEcCtD
Gadoversetamide—Shock—Capecitabine—esophageal cancer	0.00221	0.00228	CcSEcCtD
Gadoversetamide—Nervous system disorder—Capecitabine—esophageal cancer	0.0022	0.00227	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—esophageal cancer	0.0022	0.00227	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Capecitabine—esophageal cancer	0.0022	0.00227	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—esophageal cancer	0.00219	0.00227	CcSEcCtD
Gadoversetamide—Tachycardia—Capecitabine—esophageal cancer	0.00219	0.00226	CcSEcCtD
Gadoversetamide—Asthenia—Cisplatin—esophageal cancer	0.00219	0.00226	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—esophageal cancer	0.00218	0.00226	CcSEcCtD
Gadoversetamide—Skin disorder—Capecitabine—esophageal cancer	0.00218	0.00225	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00217	0.00224	CcSEcCtD
Gadoversetamide—Anorexia—Capecitabine—esophageal cancer	0.00214	0.00221	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—esophageal cancer	0.00213	0.0022	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—esophageal cancer	0.00213	0.00219	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—esophageal cancer	0.00212	0.00219	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—esophageal cancer	0.00211	0.00218	CcSEcCtD
Gadoversetamide—Hypotension—Capecitabine—esophageal cancer	0.0021	0.00217	CcSEcCtD
Gadoversetamide—Diarrhoea—Cisplatin—esophageal cancer	0.00208	0.00215	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—esophageal cancer	0.00206	0.00213	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—esophageal cancer	0.00205	0.00212	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—esophageal cancer	0.00205	0.00212	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00205	0.00211	CcSEcCtD
Gadoversetamide—Insomnia—Capecitabine—esophageal cancer	0.00203	0.0021	CcSEcCtD
Gadoversetamide—Paraesthesia—Capecitabine—esophageal cancer	0.00202	0.00208	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—esophageal cancer	0.00201	0.00207	CcSEcCtD
Gadoversetamide—Dyspnoea—Capecitabine—esophageal cancer	0.002	0.00207	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—esophageal cancer	0.00198	0.00205	CcSEcCtD
Gadoversetamide—Dyspepsia—Capecitabine—esophageal cancer	0.00198	0.00204	CcSEcCtD
Gadoversetamide—Decreased appetite—Capecitabine—esophageal cancer	0.00195	0.00202	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00194	0.002	CcSEcCtD
Gadoversetamide—Vomiting—Cisplatin—esophageal cancer	0.00194	0.002	CcSEcCtD
Gadoversetamide—Fatigue—Capecitabine—esophageal cancer	0.00194	0.002	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—esophageal cancer	0.00193	0.00199	CcSEcCtD
Gadoversetamide—Rash—Cisplatin—esophageal cancer	0.00192	0.00198	CcSEcCtD
Gadoversetamide—Pain—Capecitabine—esophageal cancer	0.00192	0.00198	CcSEcCtD
Gadoversetamide—Constipation—Capecitabine—esophageal cancer	0.00192	0.00198	CcSEcCtD
Gadoversetamide—Dermatitis—Cisplatin—esophageal cancer	0.00192	0.00198	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—esophageal cancer	0.0019	0.00196	CcSEcCtD
Gadoversetamide—Feeling abnormal—Capecitabine—esophageal cancer	0.00185	0.00191	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—esophageal cancer	0.00185	0.00191	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—esophageal cancer	0.00184	0.0019	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00184	0.0019	CcSEcCtD
Gadoversetamide—Nausea—Cisplatin—esophageal cancer	0.00181	0.00187	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—esophageal cancer	0.00179	0.00185	CcSEcCtD
Gadoversetamide—Urticaria—Capecitabine—esophageal cancer	0.00178	0.00184	CcSEcCtD
Gadoversetamide—Abdominal pain—Capecitabine—esophageal cancer	0.00177	0.00183	CcSEcCtD
Gadoversetamide—Body temperature increased—Capecitabine—esophageal cancer	0.00177	0.00183	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—esophageal cancer	0.00177	0.00183	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—esophageal cancer	0.00174	0.0018	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—esophageal cancer	0.00174	0.0018	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—esophageal cancer	0.00174	0.0018	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00173	0.00179	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—esophageal cancer	0.00172	0.00178	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—esophageal cancer	0.00169	0.00174	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—esophageal cancer	0.00167	0.00173	CcSEcCtD
Gadoversetamide—Hypersensitivity—Capecitabine—esophageal cancer	0.00165	0.00171	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—esophageal cancer	0.00164	0.00169	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—esophageal cancer	0.00164	0.00169	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—esophageal cancer	0.00162	0.00168	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—esophageal cancer	0.00162	0.00167	CcSEcCtD
Gadoversetamide—Asthenia—Capecitabine—esophageal cancer	0.00161	0.00166	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—esophageal cancer	0.00159	0.00165	CcSEcCtD
Gadoversetamide—Pruritus—Capecitabine—esophageal cancer	0.00159	0.00164	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—esophageal cancer	0.00156	0.00161	CcSEcCtD
Gadoversetamide—Diarrhoea—Capecitabine—esophageal cancer	0.00154	0.00159	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00152	0.00157	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—esophageal cancer	0.00151	0.00156	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—esophageal cancer	0.0015	0.00155	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—esophageal cancer	0.00149	0.00154	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—esophageal cancer	0.00149	0.00153	CcSEcCtD
Gadoversetamide—Dizziness—Capecitabine—esophageal cancer	0.00148	0.00153	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—esophageal cancer	0.00147	0.00152	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—esophageal cancer	0.00145	0.0015	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00144	0.00149	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—esophageal cancer	0.00144	0.00149	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—esophageal cancer	0.00143	0.00148	CcSEcCtD
Gadoversetamide—Vomiting—Capecitabine—esophageal cancer	0.00143	0.00147	CcSEcCtD
Gadoversetamide—Rash—Capecitabine—esophageal cancer	0.00142	0.00146	CcSEcCtD
Gadoversetamide—Dermatitis—Capecitabine—esophageal cancer	0.00141	0.00146	CcSEcCtD
Gadoversetamide—Headache—Capecitabine—esophageal cancer	0.00141	0.00145	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—esophageal cancer	0.00138	0.00142	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00137	0.00141	CcSEcCtD
Gadoversetamide—Nausea—Capecitabine—esophageal cancer	0.00133	0.00138	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—esophageal cancer	0.00133	0.00137	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—esophageal cancer	0.00132	0.00136	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—esophageal cancer	0.00132	0.00136	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—esophageal cancer	0.00123	0.00127	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—esophageal cancer	0.0012	0.00124	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—esophageal cancer	0.00118	0.00122	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—esophageal cancer	0.00114	0.00118	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—esophageal cancer	0.00111	0.00114	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—esophageal cancer	0.00106	0.0011	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—esophageal cancer	0.00105	0.00109	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—esophageal cancer	0.00105	0.00109	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—esophageal cancer	0.00105	0.00108	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—esophageal cancer	0.000993	0.00103	CcSEcCtD
